Research Article

Novel Compound Q-1 Alleviates Type II Collagen-Induced Arthritis in Rats through the NF-κB Pathway

Ting Xu,1,2 Jia-Chen Guo,1,3 Sha-Sha Wu,1,2 Yan Wang,1,2 Xiao-Long Liu,1,2 and Hai-Bing Qian1,2

1Guizhou University of Traditional Chinese Medicine, Guiyang, China
2Key Laboratory of General Higher Education Institutions in Guizhou Province, Guiyang, China
3Chengdu University of Traditional Chinese Medicine, Chengdu, China

Correspondence should be addressed to Hai-Bing Qian; qianhaibing337@gzy.edu.cn

Received 22 November 2020; Revised 17 May 2021; Accepted 15 June 2021; Published 1 July 2021

Academic Editor: Carmen Mannucci

Copyright © 2021 Ting Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Q-1 is a novel compound extracted from the Miao medicine Tiekuaizi. Although Q-1 is known to be a coumarin derivative, its structure has not been deposited in the ACX library. Our previous study showed that Q-1 inhibits the activity of inflammatory cells. This study explores the efficacy of Q-1 in regulating rheumatoid arthritis (RA). The findings show that Q-1 acts through the NF-κB signaling pathway. Methods. The effects of Q-1 were explored using a bovine type II collagen-induced arthritis (CIA) rat model. The CIA rats were intragastrically administered with high (30 mg·kg⁻¹) or low (15 mg·kg⁻¹) doses of Q-1. The control group was administered with an equal volume of drinking water, while the positive control group was administered with Tripterygium glycoside (9.45 mg·kg⁻¹) for 28 consecutive days. The arthritis indices and ankle joint swelling rates were determined. The levels of IL-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1) in serum and sialic acid (SA) in liver homogenate were determined by enzyme-linked immunosorbent assay (ELISA). The pathological features of the ankle joint were analyzed by hematoxylin and eosin (HE) staining. The IκB, P-IκB, P65, and P-P65 protein levels in synovial tissue were assayed by western blotting. Results. The arthritis index, ankle joint swelling rate, IL-1β, IL-6, and MCP-1 levels in serum and sialic acid (SA) in liver homogenate were determined by enzyme-linked immunosorbent assay (ELISA). The pathological features of the ankle joint were analyzed by hematoxylin and eosin (HE) staining. The IκB, P-IκB, P65, and P-P65 protein levels in synovial tissue were assayed by western blotting. The arthritis index, ankle joint swelling rate, IL-1β, IL-6, and MCP-1 levels in serum and sialic acid (SA) in liver homogenate were determined by enzyme-linked immunosorbent assay (ELISA). The pathological features of the ankle joint were analyzed by hematoxylin and eosin (HE) staining. The IκB, P-IκB, P65, and P-P65 protein levels in synovial tissue were assayed by western blotting. Results. The arthritis index, ankle joint swelling rate, IL-1β, IL-6, and MCP-1 levels in serum and sialic acid (SA) in liver homogenate were determined by enzyme-linked immunosorbent assay (ELISA). The pathological features of the ankle joint were analyzed by hematoxylin and eosin (HE) staining. The IκB, P-IκB, P65, and P-P65 protein levels in synovial tissue were assayed by western blotting.

Conclusion. The findings indicate that Q-1 effectively inhibited RA in rats by downregulating IκB, P-IκB, P65, and P-P65, inhibiting the excessive release of inflammatory factors, and inhibiting the overactivation of the NF-κB signaling pathway.

1. Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory synovial disease that results in damage to the body’s cartilage, eventually destroying bones and joints [1]. RA is clinically manifested by joint swelling and inflammation along with the proliferation of synovial cells. Disease progression damages articular cartilage and eventually the cartilage of the limbs, leading to joint deformities [2]. Currently, drugs for RA treatment are divided into six categories: nonsteroidal anti-inflammatory drugs [3], conventional synthetic disease-modifying anti-rheumatic drugs [4], biosynthetic changes in disease anti-rheumatic drugs [5], target synthetic disease-modifying anti-rheumatic drugs [6], glucocorticoids, and herbs [7]. Tripterygium glycosides have been shown to have significant immunosuppressive effects [8].

In China, the current incidence of RA is approximately 0.20%–0.37%. RA causes a high rate of disability and is extremely challenging to cure [9, 10]. In the realm of Traditional Chinese Medicine (TCM), RA belongs to the “paralysis” category and is mainly caused by a deficiency in yin and yang in the internal organs and blood channels along
with external cold. This leads to internal paralysis and the long-term loss of yang energy, resulting in yin deficiency [11]. Treatment approaches mainly focus on activating blood circulation, resolving stasis, clearing heat and dampness, and nourishing the liver and kidneys [12].

TCM is based on herbs with a long history of use. Many herbs show promise for the treatment of RA [13, 14]. Miao medicine is an important part of TCM. Tiekuaizi is a Miao medicine derived from the dried roots of members of the wax plum family, including Chimonanthus praecox (L.) Link and C. niters Oliv [15, 16]. Tiekuaizi is a common folk medicine used for treating RA in the Miao region. Previous studies have explored its chemical composition. Past studies have indicated that waxberry leaves mainly contain alkaloids, coumarins, and volatile oils. In addition, our previous studies showed that Tiekuaizi alcohol extract has an analgesic effect [17] and can effectively improve adjuvant arthritis [18, 19]. Compound Q-1, a new compound extracted from Tiekuaizi that is not found in the ACX library, has been identified as a coumarin derivative. In the present study, the anti-RA mechanism of Q-1 was explored.

2. Materials and Methods

2.1. Chemicals and Reagents. The novel compound Q-1 was isolated from Tiekuaizi in a previous study [20]. *Tripterygium* glycosides [21] (Lot 20170202) were purchased from Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co. (China). Purified Bovine Type II Natural Collagen (BNII) was purchased from Beijing Paix Science and Technology Co. (China). Incomplete adjuvant was purchased from Beijing Piaisi Technology Co., Ltd. (China). SA test kit (Lot 20190508) was purchased from the Nanjing Jiancheng Institute of Bioengineering (China). Enzyme-linked immunosorbent assay (ELISA) kits for IL-1β, IL-6, and MCP-1 (Lots R190509-113b, R190509-007b, and R190509-003b, respectively) were purchased from Simbosheng Co., Ltd. (China). IκBα, phospho-IκBα (Ser32), NF-κB P65, and phospho-NF-κB (Ser536) were obtained from Cell Signaling Technology (USA). A hematoxylin and eosin staining kit (Lot 20180608), bicinechonic acid (BCA) protein quantification kit (Lot 20190524), 5XTRIS glycine running buffer, bovine serum albumin, and Rainbow Broad Spectrum Protein MARKER (11-180KD) were obtained from Soleibao (China). Analytical reagents were purchased from China National Pharmaceutical Group Corporation.

2.2. Animals and Housing. Male Wistar rats aged 6 to 8 months with weights of 180–200 g were used in this study. Animal experiments were conducted following the China Science and Technology Ministry guidelines. Animals were handled carefully to minimize injury, discomfort, and distress. The study was approved by the Animal Ethics Committee at the Guizhou University of Chinese Medicine University (Guiyang, China) and was performed in accordance to the animal use statement. Rats were housed under specific pathogen-free conditions with a 12 h/12 h dark/light cycle. All experiments were approved and performed in accordance with National Institutes of Health Guide for Care and Use of Laboratory Animals.

2.3. Drug Administration and Experimental Design. The CIA model was prepared following a previously described protocol [22, 23]. In summary, BNII was dissolved in 0.1 M filtered acetic acid, resulting in a BNII concentration of 1 mg/ml. CIA was induced by a single intradermal injection of 0.2 ml of the above emulsion into the base of the tail at multiple sites. One week after administration, 0.1 ml of the emulsion was injected into the same site. The day of the first immunization was defined as day 0. The clinical symptoms of the rats were evaluated every three days after the onset of clinical symptoms of CIA (around 14 days after immunization). At 20 days after immunization, the CIA rats were randomly divided into the following groups: the control group comprised non-CIA and healthy control rats; the model group comprised untreated CIA rats; the positive drug control group (PCG) was administered with 9.45 mg/kg of *Tripterygium* glycosides (according to the ratio of human and rat dose of 6.13) [24]; the Q-1 high-dose group (QHG) was treated with 30 mg/kg Q-1; and the Q-1 low-dose group (QLG) was treated with 15 mg/kg Q-1 [25]. Continuous gastric administration was performed for four weeks. Joint swelling was determined based on the paw volume, which was recorded every seven days. Arthritis indices were determined using Wood’s arthritis assessment on the last day of the experiment (Figure 1).

After the experiment was completed, the rats were anesthetized via the intraperitoneal injection of urethane. Blood was collected from the abdominal aorta and centrifuged to obtain serum for the detection of IL-1β, IL-6, and MCP-1. The ankle joints were also collected and fixed in 10% formalin followed by staining. The animals’ liver and synovial tissues were collected for SA detection and western blot analysis, respectively.

2.4. Analysis of Arthritis Indices. Wood’s arthritis assessment criteria [26] were used to determine the RA indices at days 27, 34, 41, and 48. Ankle joint damage was assessed based on synovial hyperplasia, inflammatory cell infiltration, cartilage damage, and pannus formation using the following scale from 0 to 4: 0 = no changes; 1 = mild; 2 = moderate; 3 = severe; and 4 = very severe. The total pathological score of ankle joint damage was determined as the sum of the individual pathological indices (resulting in a scale from 0 to 16) once a week.

2.5. Evaluation of the Degree of Joint Swelling. The volume under the body hair of the left ankle joint was calculated using the water dissolution replacement method based on the following formula: ankle joint swelling rate = volume measured at day 20/volume measured at day 48.

2.6. ELISA. Cells were lysed using RIPA lysis buffer following the manufacturer’s protocol. Protein concentrations
were determined using BCA protein assay. Commercial ELISA kits were used to determine the levels of IL-1β, IL-6, MCP-1, and SA following the manufacturer’s instructions.

2.7. Histological Examination of Rat Knee Joints. Histological examination was performed for human synovial tissues and rat knee joints. The tissues obtained from rat knee joints were fixed with 10% formalin. The tissues were then decalcified for 20 d. The samples were embedded in paraffin, cut into 4 μm sections, deparaffinized, and rehydrated for HE staining. Paraffin sections were stained with HE and analyzed.

2.8. Western Blot Analysis. Synovial tissues or cultured fibroblast-like synoviocytes (FLS) were treated with RIPA lysis buffer containing protease inhibitors. The supernatant was obtained, and the protein level in the lysate was determined by Bradford assay. Equal amounts of proteins (50 mg) were subjected to 10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes and blocked with 5% skim milk in Tris-buffered saline. Membranes were probed with primary antibodies at 4°C overnight and incubated at 37°C with horseradish peroxidase-conjugated secondary antibodies for 2 h. Immunoreactive proteins were visualized using a Super Signal West Femto Trial Kit (Thermo Fisher Scientific, PA, USA). Protein bands were scanned and quantified by densitometry using Image J software. The relative levels of target proteins were normalized using β-actin as an internal control.

2.9. Statistical Analyses. Statistical analyses were performed using SPSS 22.0 software. Experimental data were analyzed using independent-sample T-test or one-way analysis of variance followed by least significant difference post hoc test. Pearson’s correlation test was used to explore the correlations between the expression levels of synovial IκB, P-IκB, P65, and P-P65 and the pathological parameters of rat CIA or synovial β-actin expression. Data are presented as mean ± standard error of the mean. P < 0.05 was considered to indicate statistical significance.

3. Results

3.1. Q-1 Reduces the Arthritis Index in CIA Rats. No statistically significant differences in arthritis index were observed between the model group and each treatment group on day 1 (Figure 2). The model group, PCG, QHG, and QLG all exhibited significantly higher arthritis indices on day 20 compared to the control group (P < 0.01). PCG, QHG, and QLG all exhibited significantly lower arthritis indices on day 41 compared to the model group (P < 0.05). These findings indicate that Q-1 can improve joint inflammation and reduce the arthritis index in CIA rats.

3.2. Q-1 Decreases the Rate of Ankle Joint Swelling. The model group exhibited significantly more ankle joint swelling compared to the control group (P < 0.01; Table 1). Ankle joint swelling was significantly attenuated in PCG, QHG, and QLG compared to the model group (P < 0.05 or P < 0.01). No significant differences in ankle joint swelling were observed between PCG, QHG, and QLG (P > 0.05).

3.3. Q-1 Downregulates Inflammatory Factors in CIA Rats. The model group, PCG, QHG, and QLG had significantly lower IL-1β, IL-6, and MCP-1 levels in serum and SA levels in liver tissue compared to the control group (P < 0.05 or P < 0.01; Table 2).

3.4. Compound Q-1 Alleviates Pathological Damage to the Ankle Joints of CIA Rats. No significant ankle joint damage was observed in rats in the control group (Figure 3(a)). However, rats in the model group exhibited abundant inflammatory cells (Figures 3(b) and 3(f)), indicating the successful establishment of the CIA rat model. Rats in the treatment groups exhibited significantly lower ankle joint inflammation, decreased invasion of inflammatory cells, and damage of the ankle joint compared to rats in the model group. These findings imply that Q-1 reduced changes in joint inflammation and synovial erosion in CIA rats.

3.5. Q-1 Downregulates IκB, P-IκB, P65, and P-P65 Proteins in the Synovial Tissues of CIA Rats. The levels of IκB, P-IκB,
The clinical manifestations of RA include morning stiffness, joint swelling, pain, deformity, and dysfunction, primarily in multiple small joints of the limbs. Currently, RA pathogenesis is believed to be related to heredity, autoimmunity, and environmental factors [27]. In addition to joints, RA affects other organs such as the heart and kidneys and the respiratory system.

The NF-κB signaling pathway is closely related to RA, and its activation can initiate a cascade of multiple downstream inflammatory signaling pathways to promote the secretion of inflammatory cytokines such as IL-1, IL-6, and TNF-α. NF-κB is a classical transcription factor of inflammation downstream of TLR4, mainly composed of p65 and p50 subunits to form dimer or heterodimer, which has significant pro-inflammatory activity. At rest, the p65/p50 dimer binds to the IκB inhibitor family to form a stable trimer that exists in the cytoplasm. When stimulated by extracellular signaling molecules such as cytokines and mitogens, IκB dissociates from the trimer and releases p65/p50 for nuclear translocation, which specifically binds to IκB sites on genes and initiates the expression of various inflammatory genes [28]. The IL family is highly unbalanced in RA cytokines, thereby accelerating the occurrence of RA. Thus, the IL family members are a key factor in inflammation. Studies have shown that IL-6 does not directly affect the formation of synovial cells and chondrocytes; however, it indirectly promotes the biological activity of IL-1, thereby inducing an inflammatory response. MCP-1 is a cytokine in the CC chemokine family. MCP-1 is a pro-inflammatory factor that plays an important role in the pathogenesis of RA. Therefore, the expression levels of MCP-1 cytokines can reflect the degree of RA inflammation. The proliferation of synovial cells can lead to the occurrence of RA and is the main cause of articular cartilage destruction and bone injury. SA is strongly associated with the occurrence of a variety of inflammatory diseases and malignant tumors; as an important part of protein glycosylation, SA is also closely related to RA [29]. Abnormal SA proliferation in RA patients aggravates the inflammatory response, making the RA more serious.

Previous studies have shown that immune inflammation caused by immune disorders is the leading cause of RA. RA activates the NF-κB signaling pathway, which subsequently upregulates the levels of IL-1 and IL-6, and enhances the cellular inflammatory response. The secretion of inflammatory factors induces significant infiltration of inflammatory cells, abnormal proliferation of the synovial tissue, and the mass production of neuromuscular pannus, thereby causing joint swelling and disability [29–32].

In the present study, a CIA rat model was successfully established. The pathogenesis of CIA includes two components: humoral immunity and cellular immunity. Pathological manifestations of CIA include the proliferation of T cells and B cells in the synovial tissues of joints. In RA patients, anti-collagen antibodies appear in the serum and synovial fluid. Type II collagen induces the body to produce an autoimmune response to its tissue. This response presents as an autoantigen under RA conditions. The symptoms of the CIA rat model are similar to those of RA patients, and the CIA model is currently the best model of RA. Pathological changes in CIA model rats are similar to those of RA patients. These changes can trigger autoimmunity and are controlled by major histocompatibility complex (MHC) and related genes. Monocytes invade synovial cells and persist for long time periods. This study established a CIA rat model of RA through the collagen-induced method.

The CIA model rats showed increased levels of IL-1β, IL-6, MCP-1, and SA inflammation-related factors compared to the non-CIA rats. IκB, P-IκB, P65, and P-P65 were upregulated in the model group compared to the control group. HE staining showed that the rats’ ankle joints had abundant inflammatory cells with extensive cell edema and degeneration in the model group, indicating a significant inflammatory response. Furthermore, analysis of the CIA model showed a significant activation of the NF-κB signaling pathway. Q-1 treatment significantly lowered the levels of...(continued)
IL-1β, IL-6, MCP-1, and SA inflammatory factors. Moreover, Q-1 led to the downregulation of IκB, P-IκB, P65, and P-P65 in the synovial tissues, and significantly lower levels of inflammatory cells were observed in the rat ankle joint after Q-1 treatment. These findings indicate that Q-1 has an anti-RA effect and can reduce the levels of inflammatory factors.

### Table 2: Serum IL-1, IL-6, and MCP-1 levels in CIA rats (x ± s, n = 8).

| Group   | Dosage (mg·kg⁻¹) | IL-1β (pg/ml)       | IL-6 (pg/ml)       | MCP-1 (pg/ml)      | SA (mg/gprot) |
|---------|------------------|---------------------|-------------------|--------------------|---------------|
| Control | /                | 171.67 ± 63.97      | 218.66 ± 176.93   | 1371.81 ± 274.92   | 35.51 ± 8.12  |
| Model   | /                | 624.64 ± 262.09##   | 795.95 ± 384.02## | 2106.03 ± 401.25## | 117.90 ± 21.00## |
| PCG     | 9.45             | 196.43 ± 52.20*     | 260.53 ± 260.64** | 1546.13 ± 283.40** | 66.76 ± 10.93** |
| QHG     | 30.0             | 486.24 ± 276.21**   | 324.48 ± 261.18** | 1558.94 ± 243.33** | 79.20 ± 18.10** |
| QLG     | 15.0             | 345.00 ± 275.04**   | 514.34 ± 279.32*  | 1814.07 ± 183.71*  | 95.76 ± 17.31** |

Note: # P < 0.05, ## P < 0.01 vs. the control group; * P < 0.05, ** P < 0.01 vs. the model group.

**Figure 3:** Pathological HE staining sections of the ankle joints of CIA rats: (a) control group (100×); (b) model group (100×); (c) PCG (100×); (d) QHG (100×); (e) QLG (100×); and (f) model group (40×).

**Figure 4:** Protein expression levels of IκB, P-IκB, P65, and P-P65 in the synovia of CIA rats: A, control group; B, model group; C, PCG; D, QHG; and E, QLG (#P < 0.05, ##P < 0.01 vs. the control group; * P < 0.05, ** P < 0.01 vs. the model group).
in CIA rats. The underlying mechanism by which Q-1 inhibits ankle joint inflammation involves the downregulation of IкB, P-IкB, P65, and P-P65 expression and the inhibition of the excessive activation of the NF-кB signaling pathway.

5. Conclusion

In summary, Q-1 can significantly alleviate RA in rats by downregulating the expressions of IкB, P-IкB, P65, and P-P65, in the synovial tissues, inhibiting the excessive release of inflammatory factors, and inhibiting the excessive activation of the NF-кB signaling pathway.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Ethics Committee of Guizhou University of Traditional Chinese Medicine.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Ting Xu and Jia-Chen Guo contributed equally to this study.

Acknowledgments

This research was funded by the National Natural Science Foundation of China (grant no. 81760773).

Supplementary Materials

This section includes the rates of ankle joint swelling in RA rats and serum IL-1β, IL-6, MCP-1, and SA levels in RA rats.

(Supplementary Materials)

References

[1] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid arthritis,” *Lancet*, vol. 388, no. 10055, pp. 2023–2038, 2016.
[2] Chinese Rheumatology Association, “2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis,” *Chinese Journal of Internal Medicine*, vol. 57, no. 4, pp. 242–251, 2018.
[3] S. E. Nissen, N. D. Yeomans, D. H. Solomon et al., “Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis,” *The New England Journal of Medicine*, vol. 375, no. 26, pp. 2519–2529, 2016.
[4] B. Friedman and B. Cronstein, “Methotrexate mechanism in treatment of rheumatoid arthritis,” *Joint Bone Spine*, vol. 86, no. 3, pp. 301–307, 2019.
[5] J. S. Smolen, R. Landewe, J. Bijlsma et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update,” *Ann Rheum Dis*, vol. 76, no. 6, pp. 960–977, 2017.
[6] P. C. Taylor, “Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis,” *Rheumatology (Oxford)*, vol. 58, no. Suppl 1, pp. i17–i26, 2019.
[7] T. Santiago and J. A. Da Silva, “Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years,” *Annals of the New York Academy of Sciences*, vol. 1318, pp. 41–49, 2014.
[8] S. Dudic, D. Langan, R. Meka et al., “Natural products for the treatment of autoimmune arthritis: their mechanisms of action, targeted delivery, and interplay with the host microbiome,” *International Journal of Molecular Sciences*, vol. 19, no. 9, p. 2508, 2018.
[9] H. Xiao-min, Z. Ying, Y. Shan-shan et al., “Research progress and trends in rheumatoid arthritis therapeutic drugs,” *Chinese Journal of New Drugs*, vol. 26, no. 1, pp. 36–43, 2017.
[10] B. Svensson, M. Andersson, K. Forslind et al., “Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study,” *Scandinavian Journal of Rheumatology*, vol. 4, no. 20, pp. 1–8, 2016.
[11] L. Chen-Xi, P. Wu, Z. Wen-Qin et al., “Pathogenesis of TCM syndromes related to rheumatoid arthritis,” *Human Journal of Traditional Chinese Medicine*, vol. 35, no. 7, pp. 115–117, 2019.
[12] S. Zhou and Y. Zhou, “Clinical research progress of TCM syndrome differentiation and treatment of rheumatoid arthritis,” *Clinical Journal of Traditional Chinese Medicine*, vol. 31, no. 11, pp. 2035–2038, 2019.
[13] H. Zhou, J. X. Liu, J. F. Luo et al., “Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis,” *Biochem Pharmacology*, vol. 142, pp. 133–144, 2017.
[14] L. Zhang and W. Wei, “Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paony,” *Pharmacology and Therapeutics*, vol. 207, pp. 107–452, 2020.
[15] Z. Chen-Gong and F. Yu-Lin, “HPLC fingerprint analysis of caulis of *Chimonanthus nitens* combined with chemometrics method,” *Chinese Journal of Pharmaceuticals*, vol. 52, no. 21, pp. 1944–1947, 2017.
[16] P. Li, B. Fan, Y. Liu et al., “Research progress of chemical composition and pharmacological effectiveness of helleborus thibetanus franch,” *Chinese Archives of Traditional Chinese Medicine*, vol. 32, no. 6, pp. 1286–1289, 2014.
[17] H.-B. Qian, Y. P. Xu, J.-S. Pu et al., “Study on the analgesic effect and mechanism of the ethanol extracts of Tie Kuazi,” *West China Journal of Pharmaceutical Sciences*, vol. 27, no. 3, pp. 262–264, 2012.
[18] L. Meng and H.-B. Qian, “Effects of alcohol extract from root of wintersweet on expression of HIF-1α, VEGF and MMP-3 in adjuvant arthritis rats,” *Chinese Pharmacological Bulletin*, vol. 32, no. 9, pp. 1326–1327, 2016.
[19] L. Meng, Y. Li, and H.-B. Qian, “Effects of alcohol extract from *Chimonanthus praecox* on adjuvant arthritis rats and their mechanisms,” *Journal of Liaoning University of Traditional Chinese Medicine*, vol. 31, no. Suppl 1, pp. i17–i26, 2019.
[20] Q.-Z. Zhang, X.-Y. Hu, W.-Q. Yao et al., “Pharmacologic effect of Miao medicine illicium simonsii maxim. On collagen-induced arthritis in rats,” *Eviden-based Complementary and Alternative Medicine*, vol. 11, no. 11, pp. 1–7, 2018.
[21] J. K. Yi, H. J. Kim, D. H. Yu et al., “Regulation of inflammatory response sand fibroblast-like synoviocyte apoptosis by calcineurin-binding protein 1 in mice with collagen-induced arthritis,” *Clinical and Experiental Rheumatology*
Arthritis,” *Arthritis and Rheumatology*, vol. 64, no. 7, pp. 2191–2200, 2012.

[23] X. Wang, J. Tu, J. Jiang et al., "Angiotensin II type 2 receptor modulates synovial macrophage polarization by inhibiting GRK2 membrane translocation in a rat model of collagen-induced arthritis,” *The Journal of Immunology*, vol. 12, no. 5, pp. 1–13, 2020.

[24] N. Lin, Q. Jiang, W. Liu et al., “Clinical practice guideline for tripterygium glycosides/tripterygium wilfordii tablets in treatment of rheumatoid arthritis,” *China Journal of Chinese Medicine*, vol. 45, no. 17, pp. 4149–4153, 2020.

[25] Guizhou Medical Product Administration, *Quality Standards for Chinese Medicinal Materials and Ethnic Medicinal Materials in Guizhou Province*, p. 306, Guizhou Science and Technology Press, GuiZhou, China, 2019.

[26] Q. Chen, Y. He, J. Shen et al., “Effects of bushen jiedu tongluo prescription on TLR4/IκBα/NF-κB signaling pathways related factors in type II collagen-induced arthritis rats,” *Chinese Journal of Information on TCM*, vol. 5, no. 31, pp. 1–7, 2021.

[27] G.-Y. Dong, *A Research on Genetic Pathogenic Factors of Rheumatoid Arthritis Based on Gene Co-expression Network*, Shan Dong University, Shandong, China, 2018.

[28] Q. Zhang, M. J. Lenardo, and D. Baltimore, “30 years of NF-κB: a blossoming of relevance to human pathobiology,” *Cell*, vol. 168, no. 1-2, pp. 37–57, 2017.

[29] T. Stehle and Z. M. Khan, "Rules and exceptions: sialic acid variants and their role in determining viral tropism," *Journal of Virology*, vol. 88, no. 14, pp. 7696–7699, 2014.

[30] S. Jiang and J. Lu, “Research progress of NF-κB in rheumatoid arthritis,” *Chinese Journal of Immunology*, vol. 32, no. 1, pp. 119–121, 2016.

[31] H. Nakahara, J. Song, M. Sugimoto et al., "Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis," *Arthritis Rheum*, vol. 48, no. 6, pp. 1521–1529, 2003.

[32] Y. Jung, S.-H. Ahn, H. Park et al., "Abstract 5924: necrotic cells promote microglia infiltration in glioblastoma through regulating MCP-1 and MIP-3α expression,” *Tumor Biology*, vol. 77, no. 13Suppl, pp. 5924–5928, 2017.